R&D channel feed

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

14 hours ago
AI

Gilead leans on CymaBay liv­er drug, Trodelvy read­outs and long-ac­tive PrEP yet to come this year

Yesterday
Pharma

An­oth­er quar­ter, an­oth­er Keytru­da win for Mer­ck

Yesterday
Pharma

Astel­las cuts a bis­pe­cif­ic in can­cer and a mi­to­chon­dria-fo­cused as­set from Mi­to­bridge deal

Yesterday
Pharma

Mer­ck KGaA to ex­pand Ger­man head­quar­ters with €300M+ re­search cen­ter 

Yesterday
Manufacturing

De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Yesterday
China

Astel­las' Friedre­ich’s atax­ia gene ther­a­py cleared for clin­i­cal study af­ter ear­li­er ver­sion stum­bled

2 days ago
Cell/Gene Tx

FDA's bi­o­log­ics chief Pe­ter Marks pre­views ac­cel­er­at­ed ap­proval guid­ance

2 days ago
Pharma
FDA+

Cure­Vac to cut costs, starts GSK-part­nered bird flu vac­cine tri­al

2 days ago
Pharma

To bring bold promis­es to fruition, Mod­er­na col­lab­o­rates with Ope­nAI on Chat­G­PT tech

2 days ago
Deals

Dutch biotech at­tracts J&J sup­port for can­cer pipeline in $21M Se­ries A

2 days ago
Financing

No­var­tis’ sim­pli­fied strat­e­gy takes shape as the com­pa­ny seeks for­mer Bris­tol My­ers CEO as chair

3 days ago
Pharma

Neu­ro­crine’s de­pres­sion drug pass­es Phase 2 tri­al

3 days ago

Ex­clu­sive: In $1B+ bet on AI, bio­phar­ma heavy­weights back new start­up to up­end drug R&D

3 days ago
Startups
Deals

Sanofi’s BTK in­hibitor from Prin­cip­ia deal suc­ceeds in Phase 3 im­mune throm­bo­cy­tope­nia tri­al

3 days ago

Bios­plice search­es for a path for­ward af­ter os­teoarthri­tis drug fails late-stage study

4 days ago

Ei­sai, BioArc­tic to de­vel­op new drug for Alzheimer’s that can cross blood-brain bar­ri­er

4 days ago
Deals

Boehringer In­gel­heim inks chron­ic liv­er dis­ease re­search pact with Ochre Bio

4 days ago
Deals

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Last week
In Focus

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Last week

Bris­tol My­ers pitch­es in to Pathios’ $25M Se­ries B for GPCR in­hibitor

Last week
Financing

Cerev­el notch­es Phase 3 Parkin­son's win ahead of Ab­b­Vie trans­ac­tion clos­ing

Last week

GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

Last week
Pharma

Sage nix­es pro­gram for Parkin­son’s dis­ease af­ter Phase 2 fail­ure

Last week
1234 Next page Last page
A service from the Financial Times